HomeInsightsStock Comparison

Caplin Point Laboratories Ltd vs Shilpa Medicare Ltd Stock Comparison

Caplin Point Laboratories Ltd vs Shilpa Medicare Ltd Stock Comparison

Last Updated on: May 21, 2025

Key Highlights

  • The Latest Trading Price of Caplin Point Laboratories Ltd is ₹ 2224 as of 21 May 10:09.
  • The P/E Ratio of Caplin Point Laboratories Ltd changed from 9.9 on March 2020 to 21.9 on March 2024 . This represents a CAGR of 17.21% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 12.8 on March 2020 to 125.7 on March 2024 . This represents a CAGR of 57.92% over 5 years.
  • The Market Cap of Caplin Point Laboratories Ltd changed from ₹ 2135 crore on March 2020 to ₹ 10003 crore on March 2024 . This represents a CAGR of 36.18% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 1993 crore on March 2020 to ₹ 4004 crore on March 2024 . This represents a CAGR of 14.97% over 5 years.
  • The revenue of Caplin Point Laboratories Ltd for the Mar '25 is ₹ 528.27 crore as compare to the Dec '24 revenue of ₹ 524.32 crore. This represent the growth of 0.75% The revenue of Shilpa Medicare Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 320.79 crore. This represent the decline of -100%.
  • The ebitda of Caplin Point Laboratories Ltd for the Mar '25 is ₹ 193.88 crore as compare to the Dec '24 ebitda of ₹ 193.64 crore. This represent the growth of 0.12% The ebitda of Shilpa Medicare Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 82.17 crore. This represent the decline of -100%.
  • The net profit of Caplin Point Laboratories Ltd changed from ₹ 104.23 crore to ₹ 145.28 crore over 8 quarters. This represents a CAGR of 18.06% The net profit of Shilpa Medicare Ltd changed from ₹ 1.18 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Caplin Point Laboratories Ltd changed from 9.57 % on March 2020 to 13.39 % on March 2024 . This represents a CAGR of 6.95% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.63 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Caplin Point Laboratories Ltd

  • Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16, 1990.
  • The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.
  • Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India.
  • It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections. Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries.
  • In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well.

About Shilpa Medicare Ltd

  • Shilpa Medicare Limited (Formerly known as Shilpa Antibiotics Private Limited) was incorporated as a Private Limited Company on November 20, 1987.
  • The Company changed the status to Public Limited and the name of the Company was changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
  • The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
  • It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.

Caplin Point Laboratories Ltd News Hub

News

Board of Caplin Point Laboratories recommends dividend

Caplin Point Laboratories announced that the Board of Directors of the Company at its meet...

Read more

15 May 2025 14:05

News

Caplin Steriles receives USFDA approval for Haloperidol Decanoate Injection

Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been gran...

Read more

14 May 2025 14:27

News

Caplin Point Labs subsidiary gets US FDA nod for schizophrenia treatment drug Haloperidol

The approved drug is a generic therapeutic equivalent version of the reference listed drug...

Read more

14 May 2025 13:20

News

Caplin Point Laboratories to conduct board meeting

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on ...

Read more

08 May 2025 14:47

News

Caplin Point Laboratories to conduct board meeting

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on ...

Read more

07 May 2025 17:18

News

Caplin Steriles receives USFDA approval for Phytonadione Injectable Emulsion

Caplin Point Laboratories announced that its subsidiary, Caplin Steriles, has been granted...

Read more

23 Apr 2025 12:59

Shilpa Medicare Ltd News Hub

News

Shilpa Medicare to conduct board meeting

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 26 May 202...

Read more

19 May 2025 16:26

News

Shilpa Medicare gains after arm receives EIR from USFDA for unit-1 facility

In an exchange filing, the company stated that the USFDA has classified the inspection out...

Read more

15 May 2025 09:56

News

Shilpa Medicare receives USFDA approval for Varenicline tablets

Varenicline helps people quit smoking by blocking the effect of nicotine on the brain. Nic...

Read more

09 Apr 2025 14:40

News

Shilpa Medicare receives USFDA approval for Varenicline Tablets

Shilpa Medicare has received approval from USFDA for Varenicline Tablets, 0.5 and 1 mg. Th...

Read more

09 Apr 2025 15:25

News

Shilpa Medicare rallies on BORUZU injections launch in US

BORUZU (Bortezomib for injection 3.5mg/1.4ml) is a proteasome inhibitor used for the treat...

Read more

03 Apr 2025 14:38

News

Shilpa Medicare zooms as arm partners with mAbTree Biologics for cancer drug

Under the terms of the strategic agreement, Shilpa Biologicals will support both developme...

Read more

18 Mar 2025 11:11

SWOT Analysis Of Caplin Point Laboratories Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Shilpa Medicare Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Caplin Point Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Shilpa Medicare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Caplin Point Laboratories Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Caplin Point Laboratories Ltd or Shilpa Medicare Ltd?

Market cap of Caplin Point Laboratories Ltd is 16,179 Cr while Market cap of Shilpa Medicare Ltd is 6,887 Cr

What are the key factors driving the stock performance of Caplin Point Laboratories Ltd and Shilpa Medicare Ltd?

The stock performance of Caplin Point Laboratories Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Caplin Point Laboratories Ltd and Shilpa Medicare Ltd?

As of May 21, 2025, the Caplin Point Laboratories Ltd stock price is INR ₹2128.55. On the other hand, Shilpa Medicare Ltd stock price is INR ₹704.3.

How do dividend payouts of Caplin Point Laboratories Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Caplin Point Laboratories Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions